Dual STAT‑3 and IL‑6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL‑6/IL‑6R/STAT‑3 axis

Aníbal Samael Méndez-Clemente(Universidad de Guadalajara), Georgina Hernández‐Flores(Mexican Social Security Institute)
Oncology Reports
June 14, 2022
Cited by 33


Related Papers